Introduction {#sec0005}
============

Abnormal uterine bleeding can severely affect quality of life \[[@bib0005],[@bib0010]\] and is a leading reason for outpatient contacts \[[@bib0015]\]. Adenomyosis is a common cause of abnormal uterine bleeding \[[@bib0020]\] and is known as a heterogeneous disease of the junctional zone (JZ) with ectopic endometrium infiltrating varying degrees of the myometrium. A hysterectomy may be the last resort to treat adenomyosis, but attempts with hormonal and minimally invasive treatment such as transcervical endometrial resection (TCRE) are often preferred \[[@bib0025], [@bib0030], [@bib0035], [@bib0040]\]. Adenomyosis is often found in patients who have a hysterectomy following treatment failure of TCRE \[[@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. However, of all studies assessing the effect of TCRE none have a preoperative diagnosis of adenomyosis verified by histopathology \[[@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. Thus, it is not clear whether adenomyosis is induced by TCRE or whether it is the cause of treatment failure. The number of patients with adenomyosis and a good response to the procedure is unknown due to the lack of a preoperative diagnosis of adenomyosis. The degree of JZ changes before TCRE in relation to symptom relief is of particular interest \[[@bib0070]\]. It is likely that symptoms may persist after TCRE depending on the degree of JZ changes. We hypothesized that women with more extensive down growth of the endometrium may have no or less symptom relief after TCRE compared with women with no or minimal down growth of the endometrium. Therefore, the aim of this study was to investigate the association between outcome of TCRE (symptom severity, health-related quality of life, pelvic pain and reintervention rate) and histopathological findings of the JZ.

Materials and methods {#sec0010}
=====================

Study population {#sec0015}
----------------

This prospective study was approved by The Central Denmark Region Committee of Health Research Ethics, journal number: 20010175 and The Danish Data Protection Agency, journal number: 2007-58-0010. Written informed consent was obtained from all study participants before study entry. From October 2011 to January 2015, a consecutive sample of premenopausal women undergoing TCRE due to benign abnormal uterine bleeding and/or pelvic pain was recruited at the Department of Gynecology and Obstetrics, Aarhus University Hospital, Denmark. The exclusion criteria were non-elective surgery, malignancy, mental illness, coagulopathy, lack of Danish language skills or presence of five or more leiomyomas / uterine volume \> 300 ml due to leiomyomas. Women were only able to participate once in the study project, thus repeat TCRE were excluded ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Flowchart.^1^ No adenomyosis of the inner myometrium and no reintervention surgery^2^ Five with a histopathological diagnosis of adenomyosis of the inner myometrium and no reinterventions surgery. Two with serrated junctional zone had reintervention surgery ("no adenomyosis" verified by hysterectomy)Patients with at least one follow-up questionnaire (6 or 18 months) were kept for the questionnaire analyses.Reintervention surgery was recorded for all patients who completed baseline questionnaire (n = 126).Fig. 1

Questionnaire {#sec0020}
-------------

Right before surgery, all study participants were asked to fill out a comprehensive questionnaire to obtain information on baseline characteristics, symptom severity, health-related quality of life (HR-QoL) and pelvic pain. The questionnaire was in Danish and consisted of the validated fibroid symptom and quality of life questionnaire (UFS-QOL) \[[@bib0080], [@bib0085], [@bib0090]\] including eight questions related to symptom severity (menstrual bleeding characteristics, pelvic and urinary discomfort, and fatigue) and 29 questions related to HR-QoL (concern, activities, energy/mood, control, self-consciousness, and sexual function). Each question was scored on a scale between 1 and 5. A total score was calculated and transformed into a symptom severity score (SSS) from 0 to 100 (higher score = more symptoms) and an HR-QoL score ranging from 0 to 100 (higher score = better HR-QoL). The UFS-QoL has been used for patients with adenomyosis before \[[@bib0095], [@bib0100], [@bib0105], [@bib0110]\]. Pelvic pain was assessed using the visual analogue scale for pain (VAS pain) \[[@bib0115]\], which consists of a 100-mm line with the endpoints \"no pain\" and \"worst pain\". Study participants were asked to mark the point along the line that expressed their average pain intensity. Identical questionnaires for follow-up were sent by email or post 6 and 18 months after surgery. The changes between baseline and follow-up scores (at 6 and 18 months) were calculated for SSS, HR-QoL, and VAS pain intensity. Women with an SSS \< 20, an overall HR-QoL \> 80, and no pelvic pain at 18 months follow-up were considered asymptomatic.

In addition to the questionnaires, the rate of reintervention surgery was recorded on January 2018 from the national database *Patoweb*. This is a database where all surgical pathology tests are registered.

Histopathology {#sec0025}
--------------

The procedure for obtaining deep endomyometrial biopsies during TCRE was standardized and applied in the same manner to all study participants. The surgical procedure took place in an outpatient setting with patients in local or brief general anesthesia. TCRE was performed with standardized electro current settings to avoid changes by electrocoagulation. The surgeon used a Storz resectoscope (26 F 12 oblique optic) (Karl Storz, Holte, Denmark) with a large monopolar cutting loop. To ensure that the resection could penetrate deep into the myometrium, careful suction curettage was performed immediately before resection, if the endometrium was not in the early proliferative phase. Furthermore, a firm pressure was applied to the resectoscope. Parallel slices representing the entire endometrium were obtained. Each biopsy was removed separately after each pass of the resectoscope, stretched and immediately fastened to a surface with the endometrium pointing downwards to avoid twisting. A needle was placed at the end, representing the beginning of the biopsy and the upper part of the uterus. Each biopsy was numbered according to its origin and then fixed in formalin prior to histopathological analysis.

The endometrial-myometrial JZ was defined by histopathology of endomyometrial biopsies from TCRE and defined as: Adenomyosis of the inner myometrium, ≥ 2 mm myometrial invasion without contact to the basal endometrium, serrated JZ, \> 3 mm myometrial invasion with contact to the basal endometrium, and linear JZ (no or marginal myometrial invasion ≤ 3 mm with contact to the basal endometrium) ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Left: Linear junctional zone, no or marginal myometrial invasion ≤ 3 mm with contact to the basal endometrium.Middle: Serrated junctional zone, \> 3 mm myometrial invasion with contact to the basal endometrium.Right: Adenomyosis of the inner myometrium (intrinsic adenomyosis), ≥ 2 mm myometrial invasion without contact to the basal endometrium.Fig. 2

For an accurate evaluation of the JZ, this method required thick endomyometrial biopsies with a depth of ≥ 5 mm into the myometrium. The histopathological evaluation took place within 1 to 3 weeks after surgery. The pathologist documented the findings in a standardized form designed for this study. Histopathology was inconclusive if the biopsies were either twisted or did not contain myometrium of sufficient depth (\< 5 mm). Inconclusive histopathology samples were excluded from the study.

All statistical analyses were made using STATA 13.1. The sample size calculation was based on the assumption of at least 30% reintervention among patients with adenomyosis of the inner myometrium and 5% reintervention among patients with normal JZ (linear JZ), with standard errors of 5%. The estimated required sample size was then at least n = 72. The three groups according to histopathology of the JZ (adenomyosis of the inner myometrium, serrated JZ or linear JZ) were compared using the Kruskal-Wallis one-way analysis of variance for data that were not normally distributed and one-way ANOVA for data that were normally distributed. In addition, we used the Wilcoxon signed-rank test (not normally distributed data) and student\'s *t*-test (normally distributed data) to compare patients with either adenomyosis of the inner myometrium or serrated JZ to patients with linear JZ. P-values of \< .05 were considered statistically significant. Patients who had reintervention surgery within the follow-up period (6 or 18 months) were excluded from the respective analyses. Missing items from the questionnaires were handled as follows: if \< 50% of the scale items were missing, the scale would be retained, with the mean scale score of the items present used to impute a score for the missing items (subscale analysis). If ≥ 50% of the items were missing, no scale score was calculated, and the subscale score was considered missing \[[@bib0080]\].

Results {#sec0030}
=======

In total, 112 patients filled out the baseline questionnaire. At 6 and 18 months, follow-up questionnaires were completed by 96.4% and 94,6% of the patients, respectively. Among patients who did not respond to the questionnaire, only two underwent reintervention surgery. Baseline characteristics are shown in [Table 1](#tbl0005){ref-type="table"}. The presence of intrauterine device (IUD) did not affect the histopathological results. Based on histopathology twenty-four patients (21%) had adenomyosis of the inner myometrium, 31 (28%) had serrated JZ and 57 patients (51%) had linear JZ. There was no patients with a histopathological diagnosis of adenomyomas.Table 1Baseline characteristics of patients scheduled for transcervical resection of the endometrium.Table 1All (n = 112) N95% CI 75% PI%Adenomyosis of the inner myometrium (n = 24) N95% CI 75% PI %Serrated junctional zone (n = 31) N95% CI 75% PI %Linear junctional zone (n = 57) N95% CI 75% PI %Mean age45.244-4645.544-4745.143-4745.143-47Median BMI^1^26.123-2927.124-2826.523-2924.722-29Mean number of pregnancies33-343-433-432-3Mean number of labors22-222-222-322-2Previous hysteroscopic surgery or myomectomy^2^1816%417%619%814%Previous evacuation2321%729%619%1018%Previous caesarean section1614%313%1052%35%IUD or hormonal therapy before TCRE^3^4338%417%1652%2340%IUD or hormonal therapy after TCRE^4^3430%625%1032%1832%Ultrasound diagnosis of leiomyomas (all types)2724%417%929%1425%Ultrasound diagnosis of leiomyomas\
(intramural \>3 cm in diameter or type 0-3)1624%28%516%916%Ultrasound diagnosis of polyps109%313%00%712%Mean thickness of endomyometrial biopsies5.35-65.45-65.45-65.25-5[^1][^2][^3][^4][^5][^6]

Reintervention surgery reported in the follow-up questionnaires is shown in [Table 2](#tbl0010){ref-type="table"}. In total, twelve patients (80%) underwent reintervention surgery within 18 months after TCRE and an additional three patients (20%) underwent reintervention surgery after the 18-month follow-up period and before January 2018. Reintervention surgery was performed in 33% (95% CI: 16--55) patients with adenomyosis of the inner myometrium compared to 13% (95% CI: 4--30) and 5% (95% CI: 1--15) with serrated or linear JZ respectively (p-value \< .05). Indications for reintervention surgery were either heavy menstrual bleeding and/or pelvic pain. All patients who had a reintervention surgery had a hysterectomy, but three (20%) had undergone repeated TCRE before hysterectomy. Adenomyosis of the inner myometrium was verified by histopathological examination of hysterectomy specimens in all but one woman. This woman had repeat TCRE prior to hysterectomy, thus it is likely that adenomyosis was removed before hysterectomy.Table 2Surgical reintervention during follow-up according to histopathology and clinical symptoms.Table 2Baseline symptomsSymptoms at 6 months follow-upUse of analgesics after TCRE^α^Use of IUD after TCRESurgical reintervention**HistopathologySSHR-QoLPelvic pain (VAS intensity %)SSHR-QoLPelvic pain (VAS intensity %)**\#1Adenomyosis of the inner myometrium37.556.0During (39) and between menstruation (30)Hysterectomy\#2Adenomyosis of the inner myometrium59.457.8NoRepeat TCRE^\*^\#3Serrated junctional zone53.140.5During (30) and between menstruation (15)Hysterectomy\#4^1^Linear junctional zone56.350.0During (30) and between menstruation (88)21.993.7Between menstruation (87)YesYesHysterectomy\#5Adenomyosis of the inner myometrium62.541.4During (87) and between menstruation (62)56.346.6During (90) and between menstruation (70)YesYesRepeat TCRE^\*^\#6Adenomyosis of the inner myometrium53.175.9No18.889.7During menstruation (22)YesNoRepeat TCRE^\*^\#7Adenomyosis of the inner myometrium78.142.2No43.881.0NoNoNoHysterectomy\#8Adenomyosis of the inner myometrium62.542.2During (71) and between menstruation (65)15.690.5Between menstruation (14)YesNoHysterectomy\#9^2^Linear junctional zone56.375.0During (77) and between menstruation (71)53.182.8During (56) and between menstruation (58)YesYesHysterectomy\#10Serrated junctional zone12.580.2No9.469.8Between menstruation (23)NoYesHysterectomy\#11Serrated junctional zone50.044.8During menstruation (78)Hysterectomy\#12Serrated junctional zone18.881.9During (85) and between menstruation (80)Hysterectomy\#13Adenomyosis of the inner myometrium71.963.8During (65) and between menstruation (23)6.390.5NoNoNoHysterectomy\#14Adenomyosis of the inner myometrium62.549.1During menstruation (72)53.161.2During menstruation (54)YesNoHysterectomy\#15Linear junctional zone34.430.2No65.67.8During (63) and between menstruation (60)YesNoHysterectomy[^7][^8][^9][^10][^11][^12][^13]

SSS and HR-QoL results at baseline, at 6 months follow-up (median (75% PI), 7.0 months (6--9)), 18 months follow-up (median (75% PI) and 18.4 months (18--20)) after TCRE are shown in [Table 3](#tbl0015){ref-type="table"}. In addition, [Fig. 3](#fig0015){ref-type="fig"} illustrates the HR-QoL at baseline, 6 and 18 months follow-up. There was no statistically significant difference in the baseline SSS and HR-QoL between patients with adenomyosis of the inner myometrium, serrated JZ or linear JZ. When patients with concomitant pelvic pathology (intramural leiomyomas \> 3 cm in diameter or type 0--3 leiomyomas, endometriosis and uterine polyps) were excluded from analyses, there was still no statistically significant difference between the groups (S1).Table 3Symptom severity and health-related quality of life at baseline and follow-up after transcervical resection of the endometrium.Table 3Baseline (n = 112)6 months follow-up (n = 105)^1^6 months improvement18 months follow-up (n = 96)^2^18 months improvementNMedian75% PINMedian75% PIMean95% CIDifferenceNMedian75% PIMean95% CIDifference**SSS**Adenomyosis of the inner myometrium2459.448-662218.89-4434.425-44p-value \>.05^\*^1518.86-1939.830-50p-value \> .05Serrated junctional zone3150.034-63299.46-2533.425-412810.93-1935.028-42Linear junctional zone5756.344-72547.80-2541.635-48539.43-2242.336-48**HR-QoL total**Adenomyosis of the inner myometrium2456.546-632285.869-9122.917-29p-value ≤ .051590.576-9528.621-37p-value \> .05Serrated junctional zone3156.042-662993.183-9731.022-402893.180-9730.722-39Linear junctional zone5749.140-635494.084-9836.331-415392.286-9835.429-42[^14][^15][^16][^17][^18][^19]Fig. 3Health-related quality of life on a scale from 0 to 100 at baseline, 6 and 18 months follow-up.Fig. 3

There was a statically significant difference in mean improvement of SSS and HR-QoL following TCRE between patients with either adenomyosis of the inner myometrium or serrated JZ and linear JZ at 6 months follow-up, with the most pronounced improvement among patients with linear JZ. At 18 months, when patients undergoing reintervention surgery were removed from analyses, there was no longer a statistically significant difference between the groups.

Presence and intensity of pelvic pain at baseline, and 6 and 18 months after TCRE is shown in [Table 4](#tbl0020){ref-type="table"}. There were no statistically significant differences in the distribution of patients with pain or the pain intensity between the groups at baseline. Excluding patients with concomitant pelvic pathology did not change the results significantly (S2). At 18 months follow-up, when patients with reintervention surgery were excluded, the number of patients with pelvic pain was considerably reduced and there was no significant difference in pain reduction according to histopathological findings.Table 4Pelvic pain at baseline and follow-up after transcervical resection of the endometrium.Table 4Baseline (n = 112)6 months follow-up (n = 105)^1^18 months follow-up (n = 96)^2^NWith pain N (%)VAS^\*^ Median %75% PINWith pain N (%)VAS^\*^ Median %75% PINWith pain N (%)VAS^\*^ Median %75% PI**Pelvic pain during menstruation**Adenomyosis of the inner myometrium2418 (75)6751-73227 (32)5222-67152 (13)2617-35Serrated junctional zone3121 (68)6038-68295 (17)3532-57287 (25)5950-70Linear junctional zone5745 (79)5736-705415 (28)5611-635311 (21)3120-39**Pelvic pain between menstruations**Adenomyosis of the inner myometrium2411 (46)3017-62225 (23)4219-561500Serrated junctional zone3114 (45)4024-50298 (28)2521-39283 (11)3515-53Linear junctional zone5729 (51)3925-635415 (28)375-605311 (21)4012-47[^20][^21][^22][^23][^24][^25]

In total, 31 patients had IUD's inserted after TCRE (six with adenomyosis of the inner myometrium, eight with serrated JZ and 17 with linear JZ). There was no statistically significant difference in SSS, HR-QoL and pelvic pain between the groups who had an IUD or between those with and without IUD at 18 months follow-up. Finally, at 18 months follow-up, nine patients with adenomyosis of the inner myometrium had no pelvic pain, a symptom severity score \< 20 and an HR-QoL \> 80 and were therefore considered asymptomatic.

Comment {#sec0035}
=======

Surgical reintervention after TCRE was required among 12% of the study participants, and more commonly among patients who had adenomyosis of the inner myometrium before initial TCRE than those who did not (p-value \< .05). However, TCRE completely resolved symptoms in 1/3 of all the patients with adenomyosis of the inner myometrium. A serrated JZ was rarely associated with treatment failure, although it was associated with less symptom improvement after surgery compared to linear JZ. However, the majority of all patients including those with adenomyosis of the inner myometrium and serrated JZ who did not require reintervention surgery experienced a considerable improvement in SSS and HR-QoL as well as a reduction in pelvic pain.

Previous studies have shown that TCRE is an effective treatment for abnormal uterine bleeding, particularly for heavy menstrual bleeding \[[@bib0030],[@bib0035]\], but 20% of patients might require surgical reintervention \[[@bib0120]\]. This may be due to the presence of adenomyosis \[[@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. However, to the best of our knowledge, no previous studies have evaluated the effect of TCRE according to a histopathologically proven preoperative diagnosis of adenomyosis of the inner myometrium. Moreover, outcome in relation to serrated JZ and linear JZ has not been reported. Our results suggest that TCRE does not cause adenomyosis of the inner myometrium but in fact, it seems to be an acceptable treatment option for some patients with adenomyosis of the inner myometrium and for most patients with serrated JZ or linear JZ. The cutting loop was able to penetrate at least 5 mm into the myometrium and destroy additional 1--2 mm of the myometrium due to electro-currency \[[@bib0070]\], thus we may assume that TCRE is an effective treatment option in patients with 0--7 mm endometrial penetration.

The presence of concomitant pelvic pathology did not affect our results as demonstrated in the supplementary tables (S1 + S2). This may be explained by the selection of patients without large or multiple leiomyomas. In patients with both adenomyosis and small leiomyomas, adenomyosis may be the main contributor to the clinical symptoms \[[@bib0125]\]. Furthermore, there was no difference in baseline symptoms between patients with either adenomyosis of the inner myometrium or serrated JZ and linear JZ. Again, this may be explained by the selection of only premenopausal women scheduled for surgery; anovulatory bleeding may also contribute to heavy menstrual bleeding \[[@bib0130]\] no matter the presence of adenomyosis of the inner myometrium. We were surprised not to find any difference in baseline pelvic pain between the groups. We expected that especially patients with adenomyosis of the inner myometrium and serrated JZ would have more menstrual pain because JZ changes may contribute to dysperistalsis or hyperperistalsis \[[@bib0135]\].

There are some limitations to this study. The study population was small and we did not perform a systematic preoperative imaging to determine the JZ appearance prior to surgery. A recent study suggests that preoperative two- and three-dimensional transvaginal ultrasound may differentiate between adenomyosis of the inner myometrium, serrated JZ and linear JZ \[[@bib0140]\]. Unfortunately, there is still no consistent definition of how deep the endometrial penetration must be to be diagnosed as adenomyosis of the inner myometrium. Based on previously published textbooks, we chose a definition of \> 2 mm with or without surrounding smooth muscle hyperplasia/hypertrophia \[[@bib0145],[@bib0150]\]. To determine the effect of TCRE, we assessed several subjective parameters (questionnaire) but only one objective parameter (surgical reintervention). Additional objective parameters such as the amount of menstrual blood loss may have been assessed as well. Finally, the number of patients with IUDs was very limited which may explain why we did not find a difference in symptom improvement between patients with and without IUDs.

A major strength of the study is the prospective study design of consecutively enrolled study participants undergoing the same standardized procedure for obtaining deep endomyometrial biopsies. This unique method allowed for a detailed histopathological evaluation of the entire JZ circumference. We focused not only on adenomyosis of the inner myometrium but also included serrated JZ as we hypothesized that this finding may also be associated with inferior outcome. Patients had a long-term follow-up and the response rate was high. Furthermore, we were able to gain access to information from *Patoweb* regarding surgical reintervention, even for the patients who did not complete the questionnaire.

For successful management of women suffering from chronic abnormal uterine bleeding with or without pelvic pain, it is important to consider a preoperative diagnosis of adenomyosis, as this may negatively affect the outcome of TCRE. Nevertheless, in the present study, most women with adenomyosis of the inner myometrium experienced improved clinical symptoms after TCRE. Thus, it seems possible to treat adenomyosis of the inner myometrium with a minimally invasive approach. Future studies should include a large population of women with a preoperative transvaginal ultrasound measure of endometrial penetration before undergoing TCRE. Ultrasound-guided resection \[[@bib0155]\] and routine IUD insertion after resection may further improve the outcome after endometrial ablation \[[@bib0160],[@bib0165]\].

Women with intrinsic adenomyosis are more likely to undergo reintervention surgery after transcervical endometrial resection due to persisting pelvic pain or heavy menstrual bleeding. On the other hand, approximately 1/3 of women with intrinsic adenomyosis may be asymptomatic 18 months after surgery. Overall, women with serrated and linear JZ responded well to TCRE though the highest improvement in symptoms, HR-QoL and pelvic pain was observed among women with linear JZ.
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The following are Supplementary data to this article:
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Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eurox.2019.100029>.

[^1]: CI: Confidence interval. PI: Percentile interval. BMI: Body Mass Index. IUD: Intrauterine device, TCRE: Transcervical resection of the endometrium.

[^2]: There were no statistically significant differences (p-value \<.05) between the groups (adenomyosis of the inner myometrium, serrated JZ and linear JZ) in baseline characteristics, except for mean number of pregnancies.

[^3]: ^1^One missing.

[^4]: ^2^16 had resection of polyps, one had fibroid resection and one had myomectomy.

[^5]: ^3^Three months or more prior to operation.

[^6]: ^4^Five missing.

[^7]: TCRE: Transcervical resection of the endometrium. SSS: Symptom severity. HR-QoL: Health-related quality of life. VAS: Visual analogue scale. IUD: Intrauterine device.

[^8]: \#1-3 had surgical reintervention \< 6 months after TCRE, \#4-12 had surgical reintervention 6--18 months after TCRE and \#13-15 had surgical reintervention \> 18 months after TCRE (before January 2018). Follow-up questionnaire missing in \#11 and \#12.

[^9]: \* All three patients had subsequently hysterectomy due to persisting symptoms.

[^10]: Presence or absence of adenomyosis of the inner myometrium was verified in all hysterectomy specimens except for patient \#2. This patient had one foci of adenomyosis of the inner myometrium, and it is likely that this foci may have been removed by repeat TCRE prior to hysterectomy.

[^11]: ^α^ Reported use at 6 months follow-up, including paracetamol, aspirin, non-steroidal anti-inflammatory drugs.

[^12]: ^1^ Concomitant uterine polyps.

[^13]: ^2^ Concomitant leiomyomas.

[^14]: SSS: Symptom severity score. HR-QoL: Health-Related Quality of Life. PI: Percentile interval, CI: Confidence interval.

[^15]: No subscale score was considered missing.

[^16]: ^1^ 6 months follow-up questionnaire missing in four patients (these patients did not have surgical reintervention), three patients excluded due to reintervention surgery within the follow-up period.

[^17]: ^2^ 18 months follow-up questionnaire missing in six patients (one of the patients had reintervention), ten patients exclude due to reintervention surgery within the follow-up period.

[^18]: No statistically significant difference in baseline SSS and HR-QoL between the groups (p-value \> 0.05).

[^19]: \*Statistically significant difference in 6 months follow-up SSS and HR-QoL between patients with either serrated junctional zone or adenomyosis of the inner myometrium and linear junctional zone (p-value ≤ .05).

[^20]: VAS: Visual Analogue Scale. PI: Percentile interval, CI: Confidence interval.

[^21]: \*Average pain.

[^22]: ^1^ 6 months follow-up questionnaire missing in four patients (these patients did not have reintervention surgery), three patients excluded due to reintervention surgery within the follow-up period.

[^23]: ^2^ 18 months follow-up questionnaire missing in six patients (one of the patients had reintervention), ten patients exclude due to reintervention surgery within the follow-up period.

[^24]: There was no statistically significant difference in baseline or follow-up pelvic pain and VAS intensity between groups (p-value \> 0.05).

[^25]: Before surgery more than 50% in each of the three groups used analgesic drugs; this was reduced to less than 20% at 18 months follow-up.
